Stay updated on Safety and Tolerability of Dupilumab in Atopic Dermatitis Clinical Trial
Sign up to get notified when there's something new on the Safety and Tolerability of Dupilumab in Atopic Dermatitis Clinical Trial page.

Latest updates to the Safety and Tolerability of Dupilumab in Atopic Dermatitis Clinical Trial page
- Check7 days agoNo Change Detected
- Check14 days agoNo Change Detected
- Check21 days agoChange DetectedA minor wording update in the Publications section clarifies that publications are provided voluntarily by the person entering information and relate to the study results, and the revision tag was updated from v3.2.0 to v3.3.2. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check28 days agoChange DetectedThe funding/operating status notice related to government funding interruptions has been removed.SummaryDifference0.4%

- Check42 days agoChange DetectedNo significant additions or deletions were detected on the Study Details page for NCT01385657; the content and structure appear unchanged.SummaryDifference0.3%

- Check71 days agoChange Detected- Added a government-funding notice about potential delays and updated operating status guidance, and a major version bump to v3.2.0. - Removed the previous version tag v3.1.0.SummaryDifference3%

- Check78 days agoChange DetectedAdds Revision: v3.1.0 and removes several MedlinePlus topics (Drug Safety, Counterfeit Drugs, Pharmaceutical Preparations, Substandard Drugs) and Revision: v3.0.2; overall, updates versioning and trims older topics.SummaryDifference0.5%

- Check92 days agoChange DetectedRevision updated from v3.0.1 to v3.0.2; 'Back to Top' removed. No substantive changes to core content or availability.SummaryDifference0.2%

Stay in the know with updates to Safety and Tolerability of Dupilumab in Atopic Dermatitis Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Safety and Tolerability of Dupilumab in Atopic Dermatitis Clinical Trial page.